Medical guideline

首页肿瘤学指南检索结果

检索结果

按发表年份

共搜索到9条与Recommendations.有关的结果

An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation Or Maintenance Systemic Therapy for Newly Diagnosed Stage Ii, Iii, Or Iv Epithelial Ovary, Fallopian Tube, Or Primary Peritoneal Carcinoma

2021年发布于 Current Oncology 28卷第2期 所属人体系统：其他 | 腹膜肿瘤

Ontario Health (Cancer Care Ontario)

Objective: to Provide Recommendations on Systemic Therapy Options in Consolidation Or Maintenance Therapy for Women with Newly Diagnosed Stage II III Or IV Epithelial Ovary Fallopian Tube Or Primary Peritoneal Carcinoma Including All Histological Types. Methods: Consistent with the Program in Evidence-based Program's Standardized Approach MEDLINE EMBASE PubMed Cochrane Library and PROSPERO (the International Prospective Register of Systematic Reviews) Databases and Four Relevant Conferences Were Systematically Searched. the Working Group Drafted Recommendations and Revised Them Based on the Comments from Internal and External Reviewers. Results: We Have One Recommendation for Consolidation Therapy and Eight Recommendations for Maintenance Therapy. Overall Consolidation Therapy with Chemotherapy Should Not Be Recommended in the Target Population. for Maintenance Therapy We Recommended Olaparib (Recommendation) Niraparib (Weak Recommendation) Veliparib (Weak Recommendation) and Bevacizumab (Weak Recommendation) for Certain Patients with Newly Diagnosed Stage III-IV Epithelial Ovarian Fallopian Tube Or Primary Peritoneal Carcinoma Respectively. We Do Not Recommend Some Agents as Maintenance Therapy in Four Recommendations. We Are Unable to Specify the Patient Population by Histological Types for Different Maintenance Therapy Recommendations. When New Evidence That Can Impact the Recommendations Is Available the Recommendations Will Be Updated as Soon as Possible.
指南简介 原文链接
An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation Or Maintenance Systemic Therapy for Newly Diagnosed Stage Ii, Iii, Or Iv Epithelial Ovary, Fallopian Tube, Or Primary Peritoneal Carcinoma

2021年发布于 Current Oncology 28卷第2期 所属人体系统：生殖 | 输卵管癌

Ontario Health (Cancer Care Ontario)

Objective: to Provide Recommendations on Systemic Therapy Options in Consolidation Or Maintenance Therapy for Women with Newly Diagnosed Stage II III Or IV Epithelial Ovary Fallopian Tube Or Primary Peritoneal Carcinoma Including All Histological Types. Methods: Consistent with the Program in Evidence-based Program's Standardized Approach MEDLINE EMBASE PubMed Cochrane Library and PROSPERO (the International Prospective Register of Systematic Reviews) Databases and Four Relevant Conferences Were Systematically Searched. the Working Group Drafted Recommendations and Revised Them Based on the Comments from Internal and External Reviewers. Results: We Have One Recommendation for Consolidation Therapy and Eight Recommendations for Maintenance Therapy. Overall Consolidation Therapy with Chemotherapy Should Not Be Recommended in the Target Population. for Maintenance Therapy We Recommended Olaparib (Recommendation) Niraparib (Weak Recommendation) Veliparib (Weak Recommendation) and Bevacizumab (Weak Recommendation) for Certain Patients with Newly Diagnosed Stage III-IV Epithelial Ovarian Fallopian Tube Or Primary Peritoneal Carcinoma Respectively. We Do Not Recommend Some Agents as Maintenance Therapy in Four Recommendations. We Are Unable to Specify the Patient Population by Histological Types for Different Maintenance Therapy Recommendations. When New Evidence That Can Impact the Recommendations Is Available the Recommendations Will Be Updated as Soon as Possible.
指南简介 原文链接
An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation Or Maintenance Systemic Therapy for Newly Diagnosed Stage Ii, Iii, Or Iv Epithelial Ovary, Fallopian Tube, Or Primary Peritoneal Carcinoma

2021年发布于 Current Oncology 28卷第2期 所属人体系统：生殖 | 卵巢肿瘤

Ontario Health (Cancer Care Ontario)

Objective: to Provide Recommendations on Systemic Therapy Options in Consolidation Or Maintenance Therapy for Women with Newly Diagnosed Stage II III Or IV Epithelial Ovary Fallopian Tube Or Primary Peritoneal Carcinoma Including All Histological Types. Methods: Consistent with the Program in Evidence-based Program's Standardized Approach MEDLINE EMBASE PubMed Cochrane Library and PROSPERO (the International Prospective Register of Systematic Reviews) Databases and Four Relevant Conferences Were Systematically Searched. the Working Group Drafted Recommendations and Revised Them Based on the Comments from Internal and External Reviewers. Results: We Have One Recommendation for Consolidation Therapy and Eight Recommendations for Maintenance Therapy. Overall Consolidation Therapy with Chemotherapy Should Not Be Recommended in the Target Population. for Maintenance Therapy We Recommended Olaparib (Recommendation) Niraparib (Weak Recommendation) Veliparib (Weak Recommendation) and Bevacizumab (Weak Recommendation) for Certain Patients with Newly Diagnosed Stage III-IV Epithelial Ovarian Fallopian Tube Or Primary Peritoneal Carcinoma Respectively. We Do Not Recommend Some Agents as Maintenance Therapy in Four Recommendations. We Are Unable to Specify the Patient Population by Histological Types for Different Maintenance Therapy Recommendations. When New Evidence That Can Impact the Recommendations Is Available the Recommendations Will Be Updated as Soon as Possible.
指南简介 原文链接
Management of Cardiac Disease in Cancer Patients Throughout Oncological Treatment: ESMO Consensus Recommendations

2020年发布于 Annals of Oncology 31卷第2期 所属人体系统：其他 | 癌症患者其他类问题管理

European Society for Medical Oncology

Clinical Practice Guidelines Cardiac Disease Cardiovascular Toxicity Diagnosis Recommendations.
指南简介 原文链接
Treatment of Advanced Non-small-cell Lung Cancer: the 2019 AIOM (Italian Association of Medical Oncology) Clinical Practice Guidelines

2020年发布于 Crit Rev Oncol Hematol 146卷第期 所属人体系统：呼吸 | 肺癌

Italian Association of Medical Oncology

Clinical Practice Guidelines Metastatic Disease Non-small Cell Lung Cancer Recommendations.
指南简介 原文链接
Diagnosis and Treatment of Early and Locally Advanced Non-small-cell Lung Cancer: the 2019 AIOM (Italian Association of Medical Oncology) Clinical Practice Guidelines

2020年发布于 Crit Rev Oncol Hematol 148卷第期 所属人体系统：呼吸 | 肺癌

Italian Association of Medical Oncology

Clinical Practice Guidelines Early Disease Locally Advanced Disease Non-small Cell Lung Cancer Recommendations.
指南简介 原文链接
Recommendations on Management of Gynecological Malignancies During the COVID-19 Pandemic: Perspectives from Chinese Gynecological Oncologists

2020年发布于 J Gynecol Oncol 31卷第4期 所属人体系统：生殖 | 妇科肿瘤

无

COVID-19 Gynecological Malignancies Management Pandemic Recommendations.
指南简介 原文链接
Management of Patients with High-risk and Advanced Prostate Cancer in the Middle East: Resource-stratified Consensus Recommendations

2020年发布于 World journal of urology 38卷第3期 所属人体系统：生殖 | 前列腺肿瘤

A Consortium of Urologists Medical Oncologists Radiation Oncologist and Imaging Specialists Practicing in Lebanon Syria Iraq Kuwait and Saudi Arabia

Consensus Middle East Multidisciplinary Prostate Cancer Resource-stratified Recommendations.
指南简介 原文链接
ESUR/ESUI Consensus Statements on Multi-parametric MRI for the Detection of Clinically Significant Prostate Cancer: Quality Requirements for Image Acquisition, Interpretation and Radiologists' Training

2020年发布于 European Radiology 30卷第10期 所属人体系统：生殖 | 前列腺肿瘤

European Society of Urogenital Radiology EAU Section of Urologic Imaging

Multi-parametric MRI in the Diagnostic Pathway of Prostate Cancer Has a Well-established Upfront Role in the Recently Updated European Association of Urology Guideline and American Urological Association Recommendations. • Suboptimal Image Acquisition and Reporting at an Individual Level Will Result in Clinicians Losing Confidence in the Technique and Returning to the (non-MRI) Systematic Biopsy Pathway. Therefore It Is Crucial to Establish Quality Criteria for the Acquisition and Reporting of MpMRI. • to Ensure High-quality Prostate MRI Experts Consider Checking and Reporting of Image Quality Mandatory. Prostate Radiologists Must Attend Theoretical and Hands-on Courses Followed by Supervised Education and Must Perform Regular Self- and External Performance Assessments.
指南简介 原文链接

人体系统

共搜索到9条 与Recommendations.有关的结果

2021年 发布于 Current Oncology 28卷 第2期 所属人体系统： 其他 | 腹膜肿瘤

Ontario Health (Cancer Care Ontario)

2021年 发布于 Current Oncology 28卷 第2期 所属人体系统： 生殖 | 输卵管癌

Ontario Health (Cancer Care Ontario)

2021年 发布于 Current Oncology 28卷 第2期 所属人体系统： 生殖 | 卵巢肿瘤

Ontario Health (Cancer Care Ontario)

2020年 发布于 Annals of Oncology 31卷 第2期 所属人体系统： 其他 | 癌症患者其他类问题管理

European Society for Medical Oncology

2020年 发布于 Crit Rev Oncol Hematol 146卷 第期 所属人体系统： 呼吸 | 肺癌

Italian Association of Medical Oncology

2020年 发布于 Crit Rev Oncol Hematol 148卷 第期 所属人体系统： 呼吸 | 肺癌

Italian Association of Medical Oncology

2020年 发布于 J Gynecol Oncol 31卷 第4期 所属人体系统： 生殖 | 妇科肿瘤

无

2020年 发布于 World journal of urology 38卷 第3期 所属人体系统： 生殖 | 前列腺肿瘤

A Consortium of Urologists Medical Oncologists Radiation Oncologist and Imaging Specialists Practicing in Lebanon Syria Iraq Kuwait and Saudi Arabia

2020年 发布于 European Radiology 30卷 第10期 所属人体系统： 生殖 | 前列腺肿瘤

European Society of Urogenital Radiology EAU Section of Urologic Imaging

共搜索到9条与Recommendations.有关的结果

2021年发布于 Current Oncology 28卷第2期 所属人体系统：其他 | 腹膜肿瘤

2021年发布于 Current Oncology 28卷第2期 所属人体系统：生殖 | 输卵管癌

2021年发布于 Current Oncology 28卷第2期 所属人体系统：生殖 | 卵巢肿瘤

2020年发布于 Annals of Oncology 31卷第2期 所属人体系统：其他 | 癌症患者其他类问题管理

2020年发布于 Crit Rev Oncol Hematol 146卷第期 所属人体系统：呼吸 | 肺癌

2020年发布于 Crit Rev Oncol Hematol 148卷第期 所属人体系统：呼吸 | 肺癌

2020年发布于 J Gynecol Oncol 31卷第4期 所属人体系统：生殖 | 妇科肿瘤

2020年发布于 World journal of urology 38卷第3期 所属人体系统：生殖 | 前列腺肿瘤

2020年发布于 European Radiology 30卷第10期 所属人体系统：生殖 | 前列腺肿瘤